Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc. (COLL)
Filing Type: Form 8-K (Current Report)
Date of Report: February 14, 2022
Event: Entry into a Material Definitive Agreement to acquire BioDelivery Sciences International, Inc. (BDSI).
Key Financial Metrics and Transaction Terms
- Offer Price: $5.60 per share in cash for all outstanding shares of BDSI common stock.
- Financing Facility: Collegium secured a commitment for a $650 million senior secured term loan facility from Pharmakon Advisors, L.P.
- Loan Terms:
- Interest Rate: 3-month LIBOR + 7.50% (subject to a 1.20% floor).
- Amortization: $100 million in the first year; remaining $550 million in equal quarterly installments over three years.
- Fees: 2% upfront fee at signing; 1% fee at closing.
- Termination Fee: $18,120,000 payable by BDSI to Collegium if BDSI terminates the agreement to accept a superior offer.
- Supporting Stockholders: BDSI executives and board members holding approximately 9.59% of outstanding shares have agreed to tender their shares.
Material Changes and Transaction Structure
Collegium entered into an Agreement and Plan of Merger with BDSI and its wholly-owned subsidiary, Bristol Acquisition Company Inc. The transaction structure involves:
- Cash Tender Offer: Commencing within 10 business days of the agreement date, remaining open for at least 20 business days.
- Merger: Following the tender offer, the acquisition subsidiary will merge with BDSI under Section 251(h) of the Delaware General Corporation Law, requiring no stockholder vote.
- Equity Treatment:
- Outstanding BDSI stock options with exercise prices below $5.60 will be cashed out for the excess value.
- Outstanding BDSI restricted stock units (RSUs) will be fully vested and converted to cash at the offer price.
- Warrants with exercise prices below $5.60 will be cashed out for the excess value.
Guidance, Risks, and Contingencies
Conditions to Closing: The transaction is subject to customary conditions, including the tender of more than 50% of BDSI shares and the expiration of the Hart-Scott-Rodino Antitrust waiting period.
Risks and Uncertainties: The filing highlights significant risks that could prevent the transaction from closing or alter its terms, including:
- Failure to satisfy tender offer conditions or receive regulatory approvals.
- Potential competing offers or litigation.
- Integration challenges and failure to realize anticipated synergies.
- Impact of the COVID-19 pandemic on operations.
- Regulatory and litigation risks specific to the pharmaceutical industry (e.g., opioid-related litigation).
Management Commentary: The BDSI Board unanimously approved the transaction, determined it to be in the best interests of stockholders, and recommended that stockholders accept the offer.
Investor Verification Checklist
- Verify the final tender offer materials (Schedule TO) and Solicitation/Recommendation Statement (Schedule 14D-9) once filed with the SEC.
- Confirm the status of regulatory approvals under the Hart-Scott-Rodino Act.
- Review the full Merger Agreement (Exhibit 2.1) for detailed representations, warranties, and covenants.
- Monitor the percentage of BDSI shares tendered to ensure the >50% closing condition is met.
- Assess the impact of the $650 million debt facility on Collegium's future liquidity and interest expense.